pioglitazone has been researched along with Focal Segmental Glomerulosclerosis in 5 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "While confirmatory safety and efficacy studies are needed, these findings suggest pioglitazone (a non-immunosuppressive drug) may be useful to enhance proteinuria reduction in some children and young adults with complicated NS." | 8.31 | Pioglitazone enhances proteinuria reduction in complicated pediatric nephrotic syndrome. ( Beng, HM; Hattori, M; Hidalgo, G; Hunley, TE; Miura, K; Ng, KH; Shirai, Y; Smoyer, WE; Wu, Q, 2023) |
| "While confirmatory safety and efficacy studies are needed, these findings suggest pioglitazone (a non-immunosuppressive drug) may be useful to enhance proteinuria reduction in some children and young adults with complicated NS." | 4.31 | Pioglitazone enhances proteinuria reduction in complicated pediatric nephrotic syndrome. ( Beng, HM; Hattori, M; Hidalgo, G; Hunley, TE; Miura, K; Ng, KH; Shirai, Y; Smoyer, WE; Wu, Q, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hunley, TE | 1 |
| Hidalgo, G | 1 |
| Ng, KH | 1 |
| Shirai, Y | 1 |
| Miura, K | 1 |
| Beng, HM | 1 |
| Wu, Q | 1 |
| Hattori, M | 1 |
| Smoyer, WE | 1 |
| Sharma, A | 1 |
| Bourey, RE | 1 |
| Edwards, JC | 1 |
| Brink, DS | 1 |
| Albert, SG | 1 |
| Matsushita, K | 1 |
| Yang, HC | 1 |
| Mysore, MM | 1 |
| Zhong, J | 1 |
| Shyr, Y | 1 |
| Ma, LJ | 1 |
| Fogo, AB | 1 |
| Toblli, JE | 1 |
| Ferrini, MG | 1 |
| Cao, G | 1 |
| Vernet, D | 1 |
| Angerosa, M | 1 |
| Gonzalez-Cadavid, NF | 1 |
| Zhou, TB | 1 |
| Ou, C | 1 |
| Luo, CP | 1 |
| Xu, HL | 1 |
5 other studies available for pioglitazone and Focal Segmental Glomerulosclerosis
| Article | Year |
|---|---|
Pioglitazone enhances proteinuria reduction in complicated pediatric nephrotic syndrome.
Topics: Child; Glomerulosclerosis, Focal Segmental; Humans; Nephrotic Syndrome; Pioglitazone; Proteinuria; S | 2023 |
Nephrotic range proteinuria associated with focal segmental glomerulosclerosis reversed with pioglitazone therapy in a patient with Dunnigan type lipodystrophy.
Topics: Adult; Female; Glomerulosclerosis, Focal Segmental; Humans; Hypoglycemic Agents; Kidney Diseases; Li | 2021 |
Effects of combination PPARγ agonist and angiotensin receptor blocker on glomerulosclerosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Blood Pressure; Creatinine; Diseas | 2016 |
Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus.
Topics: Animals; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Fibrosis; Glomerulosclerosis, Focal | 2009 |
Protective effects of PPARγ agonist in glomerulosclerosis rats induced by adriamycin.
Topics: Animals; Antibiotics, Antineoplastic; Doxorubicin; Glomerulosclerosis, Focal Segmental; Hypoglycemic | 2012 |